- Home
- ACRV vs MMTX Comparison
ACRV vs MMTX Comparison
Compare ACRV & MMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACRV | MMTX |
|---|---|---|
| Founded | 2018 | 2025 |
| Country | United States | Taiwan |
| Employees | N/A | 2 |
| Industry | Medicinal Chemicals and Botanical Products | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.2M | 88.9M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | ACRV | MMTX |
|---|---|---|
| Price | $1.60 | $10.08 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $11.67 | N/A |
| AVG Volume (30 Days) | ★ 493.5K | 10.5K |
| Earning Date | 05-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 15.13 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $568.17 | N/A |
| P/E Ratio | ★ N/A | $139.74 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.05 | $9.89 |
| 52 Week High | $3.56 | $10.09 |
Technical Indicators
Market Signals| Indicator | ACRV | MMTX |
|---|---|---|
| Relative Strength Index (RSI) | 39.00 | 74.41 |
| Support Level | $1.51 | $9.90 |
| Resistance Level | $1.86 | $10.09 |
| Average True Range (ATR) | 0.12 | 0.01 |
| MACD | -0.04 | -0.00 |
| Stochastic Oscillator | 1.09 | 75.00 |
Price Performance
Historical ComparisonAbout ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.
About MMTX Miluna Acquisition Corp Class A Ordinary Share
Miluna Acquisition Corp is a blank check company.